{"id":"W2001182126","doi":"10.1200/jco.2007.11.2839","title":"Docetaxel Plus Cyclophosphamide in Adjuvant Breast Cancer","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Docetaxel; Cyclophosphamide; Oncology; Adjuvant; Breast cancer; Internal medicine; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001880497,0.0003521792,0.0008877876,0.0004151719,0.0005157446,0.001000696,0.0005744926,0.004663004,0.002915523],"category_scores_gemma":[0.003291188,0.0002644243,0.0005780113,0.0004944302,0.0006685934,0.001027672,0.0003464769,0.005752951,0.002107129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001790932,"about_ca_system_score_gemma":0.0008540135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008798326,"about_ca_topic_score_gemma":0.004858266,"domain_scores_codex":[0.9993783,0.0001821577,0.0001194476,0.00006502848,0.0001745586,0.00008039393],"domain_scores_gemma":[0.9989201,0.0006340244,0.0001188097,0.00004614148,0.0001463734,0.0001345453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001146114,0.0001978322,0.002547542,0.001223646,0.0001116248,0.008459625,0.00008920882,0.0004403366,0.001864603,0.006646784,0.608116,0.3691566],"study_design_scores_gemma":[0.0006121795,0.0004665555,0.004626899,0.0007955628,0.000105337,0.01047476,0.0001135581,0.0006224425,0.0008684923,0.006403083,0.9748799,0.00003134608],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.01003396,0.2166872,0.000755969,0.6893021,0.05460758,0.00012894,0.0002760606,0.00009572182,0.02811242],"genre_scores_gemma":[0.09034394,0.1523478,0.001798229,0.5599025,0.1682291,0.0002522214,0.0003076349,0.00006160372,0.02675691],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.004663004,"threshold_uncertainty_score":0.01299411,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1472986390911163,"score_gpt":0.5105592915120212,"score_spread":0.3632606524209049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}